frontmind: tafasitamab lenalidomide r-chop vs r-chop for newly diagnosed high-risk dlbcl
Published 1 year ago • 203 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:20
frontmind: tafasitamab lenalidomide r-chop vs r-chop in newly diagnosed high-risk dlbcl
-
3:53
frontmind: tafasitamab lenalidomide r-chop vs r-chop in high-intermediate & high-risk dlbcl
-
1:28
first-mind: phase ib study of r-chop tafasitamab ± lenalidomide in newly diagnosed dlcbl
-
1:36
the use of tafasitamab and lenalidomide in r/r dlbcl
-
2:23
re-mind2: observational study comparing tafasitamab lenalidomide to available therapies in r/r dlbcl
-
1:35
long-term follow-up of tafasitamab and lenalidomide in r/r dlbcl
-
2:50
tafasitamab-lenalidomide in r/r dlbcl: clinical trial results and real-world data
-
1:41
real-world efficacy of tafasitamab lenalidomide in r/r dlbcl & the importance of patient selection
-
1:03:59
reweaving the rainbow
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
5:25
what does the nanoneedle research mean for me/cfs patients?
-
3:12
tafasitamab at the blood-brain barrier: exploring this agent for the treatment of cns lymphoma
-
1:46
r-chop versus r-bendamustine in fl
-
2:13
tafasitamab plus lenalidomide post-cd19 car-t is associated with poor outcomes in lbcl
-
1:28
magnetismm-7: elranatamab vs lenalidomide following autohsct in mrd-positive newly diagnosed myeloma
-
2:41
an overview of the latest advances in hematology
-
0:56
real-world survival in patients with mixed phenotype attr-cm treated with tafamidis
-
1:21
olympia-5: odronextamab lenalidomide for r/r indolent lymphoma
-
2:31
long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in r/r fl
-
2:56
moving towards chemotherapy-free approaches in r/r follicular lymphoma
-
1:08
an insight into the mutational landscape and unique features of cmml
-
1:39
the mechanism of action of navtemadlin and its role in mf